

Synthetic lethal interaction between the tumour suppressor *STAG2* and its paralog *STAG1*

Lorena Benedetti^{1,2}, Matteo Cereda^{1,2}, LeeAnn Monteverde^{1,2}, Nikita Desai^{1,2} and Francesca D. Ciccarelli^{1,2}

¹Division of Cancer Studies, King's College London, London SE1 1UL, UK

²Cancer Systems Biology Laboratory, The Francis Crick Institute, London NW1 1AT, UK

Correspondence to: Francesca D. Ciccarelli, **email:** francesca.ciccarelli@kcl.ac.uk

Keywords: synthetic lethality, cohesin complex, paralog dependency, cancer vulnerability, precision medicine

Received: September 20, 2016

Accepted: March 08, 2017

Published: April 05, 2017

Copyright: Benedetti et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Cohesin is a multi-protein complex that tethers sister chromatids during mitosis and mediates DNA repair, genome compartmentalisation and regulation of gene expression. Cohesin subunits frequently acquire cancer loss-of-function alterations and act as tumour suppressors in several tumour types. This has led to increased interest in cohesin as potential target in anti-cancer therapy. Here we show that the loss-of-function of *STAG2*, a core component of cohesin and an emerging tumour suppressor, leads to synthetic dependency of mutated cancer cells on its paralog *STAG1*. *STAG1* and *STAG2* share high sequence identity, encode mutually exclusive cohesin subunits and retain partially overlapping functions. We inhibited *STAG1* and *STAG2* in several cancer cell lines where the two genes have variable mutation and copy number status. In all cases, we observed that the simultaneous blocking of *STAG1* and *STAG2* significantly reduces cell proliferation. We further confirmed the synthetic lethal interaction developing a vector-free CRISPR system to induce *STAG1/STAG2* double gene knockout. We provide strong evidence that *STAG1* is a promising therapeutic target in cancers with inactivating alterations of *STAG2*.

INTRODUCTION

Cohesin is an evolutionarily conserved complex composed of four core proteins (SMC1A, SMC3, RAD21 and either *STAG2* or *STAG1*) that form a ring-shaped structure able to encircle chromatin [1]. In somatic cells, cohesin is responsible for the cohesion of sister chromatids and proper chromosome segregation during mitosis [1, 2]. Besides this canonical role, cohesin is involved in a plethora of other functions including DNA replication and repair, regulation of gene expression and genome compartmentalisation [3, 4]. All cohesin components, except *STAG1*, have tumour suppressor roles in several cancer types, including leukaemia, sarcoma, glioblastoma and bladder cancer [5]. The mechanism by which altered cohesin contributes to cancer is still unclear. It has been proposed that defects in chromatid cohesion may be responsible for cancer aneuploidy and increased genomic instability [3, 6]. However, several cancers with inactivating alterations in

the cohesin complex maintain a nearly normal karyotype. This led to speculation that the alteration of other cohesin functions, such as transcriptional deregulation or defective DNA repair, may contribute to cancer [7, 8].

Given their widespread tumour suppressor activity, cohesin proteins are of obvious clinical interest for the development of targeted cancer therapy. However, tumour suppressors are difficult to target directly because they require agonists or activators that are able to rescue the lost functions. An alternative strategy is to target tumour suppressors indirectly by interfering with their synthetic lethal partners. Synthetic lethality indicates a genetic interaction where the concomitant alteration of two nonessential genes leads to cell death while the alteration of either gene individually is viable. Blocking synthetic lethal partners of tumour suppressor genes is a powerful way to selectively kill cancer cells where they are inactive, while the normal cells remain viable because the genes are wild-type (WT) [9]. Synthetic lethality is the outcome of different

types of genetic interactions that make the cell resilient to single gene loss, including back up pathways, rewired intracellular networks or functional compensation due to genetic redundancy. Genes that originate via duplication (paralogs) are interesting candidates for functional compensation because paralogs often preserve some degree of redundancy. Therefore, the identification of ‘paralog dependencies’ is an emerging strategy to uncover cancer vulnerabilities of potential relevance in cancer therapy [10].

Here we investigate whether paralog dependency is established in cancers that acquire loss-of-function (LoF) alterations in the cohesin complex. We focus specifically on *STAG1* and *STAG2* because they are duplicated cohesin subunits that are both expressed in somatic cells. Using a variety of experimental approaches and cell lines, we show that *STAG1* and *STAG2* are synthetic lethal partners and provide evidence that *STAG1* is a potential therapeutic target in tumours where *STAG2* is inactive.

RESULTS

Evidence of functional compensation between *STAG1* and *STAG2*

STAG1 and *STAG2* encode two proteins with 70% amino acid identity and the same domain organisation (Figure 1A). These proteins are mutually exclusive subunits of two distinct cohesin complexes – cohesin SA1 and cohesin SA2 – that have undergone partial subfunctionalization while still preserving overlapping functions [3] (Figure 1B). For example, both complexes mediate chromatid cohesion along chromosome arms [11, 12], while cohesin SA1 and cohesin SA2 tether telomeric and centromeric sister chromatids, respectively [11]. Additionally, the two complexes play both overlapping and distinct roles in gene expression regulation [12] and in DNA damage checkpoint in response and repair [13]. Interestingly, the depletion of *STAG1* in HeLa cells results in increased *STAG2* expression and *vice versa*, thus suggesting some degree of compensation between the two genes [13]. However, so far the functional interaction between these two genes has not been investigated in detail.

Both *STAG1* and *STAG2* acquire somatic LoF alterations (homozygous gene deletions, truncating mutations and multiple hits; see Methods) as well as putative damaging missense and splicing mutations in a variety of human cancers of The Cancer Genome Atlas (TCGA, Figure 1C). However *STAG2*, but not *STAG1*, has been identified as a tumour suppressor in leukaemia, sarcoma, glioblastoma and bladder cancer [14–20] (Table 1). This may be due to the localisation of *STAG2* on the X chromosome that makes a single hit sufficient to inactivate the gene. LoF alterations are clearly associated with a significant reduction of *STAG2* expression in cancer cell lines and in TCGA samples (Figure 1D), supporting a reduced gene activity after somatic inactivation. Also, *STAG1* expression slightly increases in cell lines with LoF alterations in *STAG2*, although this is not observed in human samples (Figure 1E). Therefore,

despite the effects of *STAG2* depletion on *STAG1* expression seem context-specific (see also below), in some cases it may lead to increased levels of *STAG1*. This, coupled with high sequence identity and partially overlapping functions, suggests a functional compensation, and possibly a synthetic lethal interaction, between the two genes.

Transient gene knockdown validates synthetic lethality between *STAG1* and *STAG2*

To validate the predicted synthetic lethal interaction between *STAG1* and *STAG2*, we inactivated them in the CAL-51 cancer cell line where both genes are WT (Supplementary Table 1). We knocked down each gene individually or both simultaneously with gene-specific short interfering RNAs (siRNAs), using negative siRNAs as a control (Supplementary Table 2). First, we confirmed decreased mRNA levels and undetectable protein expression of the knocked down genes (Figure 2A). Then we measured cell proliferation 24, 48, 72 and 96 hours after transfection. To ensure that these measures were comparable across replicates and independent of the number of initially seeded cells in each condition, we normalised each time point to the value measured at 24 hours. We found that viable cells after the simultaneous silencing of *STAG1* and *STAG2* were significantly lower than the control (Figure 2B), supporting synthetic lethality between the two genes. Crystal violet staining of CAL-51 cells 120 hours after transfection confirmed that the double knockdown (KD) of *STAG1* and *STAG2* led to a drastic reduction in the number of cells (Figure 2C). To test whether the observed effect was universal or rather specific to CAL-51 cells, we repeated the KD experiment in MCF-7 breast cancer cells, another cell line in which both genes are WT (Supplementary Table 1). Interestingly, *STAG2* expression in MCF-7 cells increased when *STAG1* was knocked down (Figure 2D), in agreement with what has been previously reported in HeLa cells [13]. However, the same signal was not observed in CAL-51 cells (Figure 2A), suggesting that the changes in the relative expression of the two genes are context-specific. We then monitored the effect of the individual or simultaneous blocking of *STAG1* and *STAG2* on MCF-7 cell proliferation as compared to the control. As we found for CAL-51, the proliferation of MCF-7 was significantly impaired in the presence of the double KD of *STAG1* and *STAG2* (Figure 2E). Finally, we tested whether the inhibition of *STAG1* alone was enough to reduce cell proliferation when *STAG2* was already inactive. This condition mimics that of cancer samples where *STAG2* is somatically inactivated and supports the development of *STAG1* as a therapeutic target in these tumours. To test this, we used SK-ES-1, a sarcoma cell line with a somatic homozygous point mutation in *STAG2* (Supplementary Table 1). This mutation introduces a premature stop codon (Figure 2F) resulting in the abolishment of the full-length *STAG2* protein expression (Figure 2G). We knocked down *STAG1* via siRNA (Figure 2H) and monitored its effect on cell growth. However,




Figure 1: Evidence of functional compensation between STAG1 and STAG2. Legend: (A) Sequence identity and domain architecture of STAG1 and STAG2 proteins as annotated in the SMART database [57]. **(B)** Composition and biological functions of cohesin SA1 and cohesin SA2. **(C)** Fraction of TCGA cancers with LoF alterations (homozygous gene deletions, truncating mutations and multiple hits) or damaging missense and splicing mutations in *STAG1* or *STAG2* divided by tumour type. The total number of sequenced samples in TCGA is reported in brackets. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; COAD, colon adenocarcinoma; ESCA, oesophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukaemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumours; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma. **(D)** Expression profiles of *STAG2* when it acquires damaging or LoF alterations as compared to when it is WT in cancer cell lines from the Cell Line Project (CLP, http://cancer.sanger.ac.uk/cell_lines) and in TCGA samples and. **(E)** Expression profiles of *STAG1* when *STAG2* acquires damaging or LoF alterations as compared to when it is WT in CLP cell lines and in TCGA samples. The numbers of mutated samples or cell lines are reported in brackets. Distributions were compared using the Wilcoxon test and corresponding p-values are shown; ns = not significant.

Table 1: Cancer driver role and paralogy relationship of human cohesin subunits

Cohesin subunit	Cancer type	Reference(s)	Paralog(s)
SMC3	Acute myeloid leukaemia	[7, 58, 59]	No
SMC1A	Urothelial bladder	[14]	SMC1B*
	Acute myeloid leukaemia	[7, 59]	
RAD21	Acute myeloid leukaemia	[59, 60]	RAD21L*
STAG2	Urothelial bladder	[14–17]	STAG1, STAG3*
	Acute myeloid and lymphoblastic leukaemia	[7, 59, 61, 62]	
	Paediatric and adult Ewing sarcoma	[18, 19, 63]	
	Glioblastoma	[20]	

Reported are the cancer types and associated studies where somatic modifications of the cohesin subunit are cancer drivers.

* = active in meiosis.

the measure of SK-ES-1 cell proliferation via enzymatic activity yielded inconsistent results even for untreated cells (Supplementary Figure 1A). This is likely because SK-ES-1 cells tend to form aggregates (Supplementary Figure 1B) that prevent uniform incorporation of the reagents needed for the assay. Therefore, instead of measuring cell proliferation, we counted the number of SK-ES-1 cells 96 hours after transfection with negative siRNAs or *STAG1* siRNA. Each transfection was repeated six times and cells were counted blindly and independently by two operators. We found that the number of cells after of *STAG1* KD was significantly lower than the control (Figure 2I). Although we did not detect any full-length protein (Figure 2G), *STAG2* mRNA is still expressed in SK-ES-cells according to the gene expression profile of the cancer cell line project [21]. To rule out the possibility that a truncated version of *STAG2* protein was still functional, we knocked down both genes. We confirmed that the simultaneous KD of *STAG1* and *STAG2* had no further detrimental effect on the proliferation of SK-ES-1 cells (Figure 2I). Therefore, the blocking of *STAG1* alone is sufficient to impair cell growth when *STAG2* is inactive.

Stable gene knockout of *STAG1* and *STAG2* confirms synthetic lethality

Next, we tested whether the synthetic lethal interaction between *STAG1* and *STAG2* could be confirmed through stable knockout (KO) of *STAG1* or *STAG2* in addition to transient KD of the respective paralog. To stably inactivate *STAG2*, we developed a vector-free (vf) CRISPR system (Figure 3A). First, we induced Cas9 expression in CAL-51 cells (Figure 3B). We then transfected CAL-51 Cas9 expressing cells with a universal trans-activating RNA (tracrRNA) and three different *STAG2*-specific CRISPR targeting RNAs (crRNAs, Supplementary Table 2). We selected the optimal *STAG2* crRNA based

on editing efficiency (Figure 3C) and used it in further experiments. Starting from a heterogeneous population of *STAG2*-edited cells, we performed single cell cloning and identified a clone with homozygous *STAG2* editing using the High Resolution Melting assay (Figure 3D). Sequencing of the edited region confirmed a homozygous eight-nucleotide-long deletion producing a frameshift in the *STAG2* protein after Leucine 161 (L161fs-*STAG2*, Figure 3E). We detected no *STAG2* mRNA (Figure 3F) or protein (Figure 3G) expression in CAL-51 L161fs-*STAG2* cells. To test the synthetic lethal interaction between *STAG1* and *STAG2* in the presence of stably inactivated *STAG2*, we transfected CAL-51 L161fs-*STAG2* cells with either *STAG1* siRNA or negative siRNA. We found that cell proliferation 96 hours after transfection with *STAG1* siRNA was significantly lower than the control (Figure 3H).

To stably inactivate *STAG1*, we infected CAL-51 cells with a lentiviral vector containing Cas9sp, an antibiotic resistance marker, and a *STAG1* guide RNA (gRNA, Figure 4A, Supplementary Table 2). After antibiotic selection, we obtained *STAG1* CAL-51 edited cells (CAL-51 crVector-*STAG1*, Figure 4B). Although *STAG1* mRNA level in CAL-51 crVector-*STAG1* cells was comparable to the control (Figure 4C), no *STAG1* protein was detected (Figure 4D). We then transfected CAL-51 crVector-*STAG1* cells directly with either *STAG2* siRNA or negative siRNA. Again, we found that the silencing of *STAG2* significantly reduced the proliferation of crVector-*STAG1* cells as compared to the control (Figure 4E). Using a similar approach, we generated stable *STAG1* KO in sarcoma (U2OS), uterine carcinoma (MFE-319) and bladder carcinoma (RT-112) cell lines that have both genes WT, but with a different number of copies (Supplementary Table 1). We first induced *STAG1* editing (Figure 4F) and then transfected the cells with *STAG2* or control siRNAs, observing significant reduction of cell proliferation only when both genes were blocked (Figure 4G).

As a final validation, we measured the effect of the stable KO of both *STAG1* and *STAG2* in two different experimental settings. In the first experimental setting, we compared the growth of CAL-51 L161fs-*STAG2* cells and CAL-51 Cas9 cells after infection with the *STAG1*

Cas9 lentiviral vector (Figure 5A). Crystal violet staining showed that while *STAG1* edited cells reached around 75% confluence after ten days of antibiotic selection, the double editing of both genes critically reduced the number of cells (Figure 5B). In the second experimental setting,




Figure 2: Effect of transient blocking of *STAG1* and *STAG2* on cell proliferation. Legend: (A) *STAG1* and *STAG2* gene (left) and protein (right) expression in CAL-51 cells 48 hours and 72 hours after siRNA transfection, respectively. (B) Proliferation curve of CAL-51 cells after transfection with negative, *STAG1* and *STAG2* siRNAs. Three biological replicates were done and the KD was repeated three times in each replicate. (C) Crystal violet staining of CAL-51 cells 120 hours after transfection with negative, *STAG1* and *STAG2* siRNAs. (D) *STAG1* and *STAG2* expression measured by quantitative RT-PCR in MCF-7 cells 72 hours after siRNA transfection. (E) Proliferation curve of MCF-7 cells after transfection with negative, *STAG1* and *STAG2* siRNAs. Two biological replicates were done and the KD was repeated three times in each replicate. (F) Sanger sequencing confirmation of *STAG2* homozygous nonsense mutation in SK-ES-1 cells. (G) Immunoblots of *STAG1* and *STAG2* protein expression in untreated SK-ES-1 cells. (H) *STAG1* mRNA expression in SK-ES-1 cells after siRNA transfection as compared to the control. (I) Number of SK-ES-1 cells 96 hours after transfection of *STAG1* or *STAG1* and *STAG2* siRNAs as compared to the control. Each KD was repeated six times and cells were counted blindly and independently. Average number of cells and associated standard errors across replicates for each condition are shown. Means were compared using one-tailed Student's t-test. In all quantitative RT-PCR experiments, β -2-microglobulin was used for normalisation. Shown are mean and standard error of normalized expression values across replicates. In all proliferation curves, Relative Fluorescent Unit (RFU) values were normalised to the mean across replicates at 24 hours. Mean values at 96 hours were compared using the one-tailed Student's t-test; ns = not significant.

we used the vf-CRISPR system to edit *STAG1* in both CAL-51 L161fs-STAG2 cells and CAL-51 Cas9 cells (Figure 5C). Here the expectation was that because of synthetic lethality, *STAG1* editing should be significantly less efficient in CAL-51 L161fs-STAG2 cells as compared to CAL-51 Cas9 cells. As we did for STAG2, we tested three different STAG1 crRNAs and used the one with the highest editing efficiency (Supplementary Figure 2A). Moreover, we added Cas9 protein to the transfection mix after verifying that this further improves the editing efficiency (Supplementary Figure 2B). As a further control

to rule out the possibility that *STAG2* KO would interfere with any additional gene editing, we edited *EMX1*, an unrelated gene that is broadly used as a positive control for CRISPR-induced gene editing [22, 23], in both cell lines under the same conditions used to edit *STAG1* (Figure 5C). While we observed comparable *EMX1* editing efficiency in CAL-51 L161fs-STAG2 cells and in CAL-51 Cas9 cells, *STAG1* editing was clearly detectable in CAL-51 Cas9 cells but almost absent in CAL-51 L161fs-STAG2 cells (Figure 5D). Quantification of the gel bands corresponding to the edited regions confirmed no difference in the




Figure 3: Synthetic lethality between STAG1 and STAG2 in stably edited *STAG2* cells. Legend: (A) Schematic diagram to derive *STAG2* KO clones via vector-free (vf) CRISPR editing. CAL-51 cells are first infected with a Cas9 containing lentiviral vector to induce Cas9 expression and then transfected with a universal trans-activating RNA (tracrRNA) and gene-specific CRISPR targeting RNAs (crRNAs). Finally, edited clones are isolated via single cell cloning. (B) Evidence of Cas9 mRNA expression in CAL-51 Cas9 cells. (C) T7 endonuclease 1 assay (T7E1) assay on the edited regions of *STAG2* after transfection with three *STAG2*-crRNAs. *STAG2b* (red box) was selected because of its higher editing efficiency. (D) High Resolution Melting Assay on isolated clones after single cell cloning from a heterogeneous population of *STAG2* edited cells. The assay was used to identify clones with homozygous *STAG2* editing. (E) Sanger sequencing confirmation of the eight-base-pair-long homozygous deletion in CAL-51 L161fs-STAG2 cells. (F) Expression of *STAG2* via quantitative RT-PCR in CAL-51 L161fs-STAG2 cells and in CAL-51 Cas9 cells. β -2-microglobulin was used for normalisation. Shown are mean and standard error of normalized expression values across replicates. (G) Western blots of *STAG2* protein expression in CAL-51 L161fs-STAG2 cells and CAL-51 Cas9 cells. (H) Proliferation curve of CAL-51 L161fs-STAG2 cells after transfection with negative or *STAG1* siRNAs. Three biological replicates were done and the KD was repeated three times in each replicate. Relative Fluorescent Unit (RFU) values were normalised to the mean across replicates at 24 hours. Mean values at 96 hours were compared using the one-tailed Student's t-test.

fraction of *EMX1* editing and a significantly lower fraction of *STAG1* editing in CAL-51 L161fs-STAG2 cells as compared to CAL-51 Cas9 cells (Figure 5E). This excludes the possibility that CAL-51 L161fs-STAG2 cells are resistant to additional gene editing and proves specific counter selection of *STAG1* and *STAG2* simultaneous KO due to the synthetic lethality between the two genes.

DISCUSSION

The cohesin complex has recently attracted increased attention as an interesting therapeutic target because of its frequent somatic inactivation in cancer. For example, it has been shown that, *STAG2*-deficient glioblastoma cells, although not *STAG2*-deficient Ewing sarcoma cells [24], are more responsive than *STAG2* proficient cells to

treatment with PARP inhibitors [25]. Synthetic lethality between cohesin and PARP has been explained by their respective roles in recovering and maintaining the integrity of stalled replication forks [26]. In the presence of defective cohesin, cancer cells become dependent on replication fork mediators, such as PARP, to replicate the genome correctly and efficiently [27]. When these mediators are also inhibited, the replication fork cannot progress resulting in double strand breaks [26]. This is an example of synthetic lethality resulting from the concomitant inhibition of two independent pathways that are nonessential *per se* but that both contribute to an essential process – in this case DNA replication. Cells with altered cohesin are also sensitive to the inhibition of the anaphase promoting complex/cyclosome (APC/C), which is required for exiting mitosis after proper chromosome segregation [28]. In this case, synthetic lethality between




Figure 4: Synthetic lethality between *STAG1* and *STAG2* in stably edited *STAG1* cells. Legend: (A) Schematic representation of vector-mediated *STAG1* editing. Cells were infected (CAL-51) or transfected (U2OS, MEF-319, RT-112) with a *STAG1*-Cas9 vector. Resulting *STAG1* edited cells were subsequently isolated (see Methods). **(B)** T7E1 assay on *STAG1* edited region in crVector-*STAG1* CAL-51 cells. **(C)** *STAG1* expression in CAL-51 Cas9 and crVector-*STAG1* cells. β -2-microglobulin was used for normalisation. Shown are mean and standard error of normalized expression values across replicates. **(D)** Western blots of *STAG1* in CAL-51 Cas9 cells and crVector-*STAG1* cells after transfection with negative or *STAG2* siRNAs. **(E)** Proliferation curve of CAL-51-Cas9 and crVector-*STAG1* cells after transfection with negative or *STAG2* siRNAs. **(F)** T7E1 assay on *STAG1* edited region in crVector-*STAG1* U2OS, MFE-319, and RT-112 cells, respectively. **(G)** Proliferation curve of U2OS, MFE-319, and RT-112-Cas9 and corresponding crVector-*STAG1* cells after transfection with negative or *STAG2* siRNAs. All proliferation assays were done in triplicates, except for MFE-319 where two replicates were performed, and the KD was repeated three times in each replicate. Relative Fluorescent Unit (RFU) values or Optical Density at 570 nm (OD-570) values were normalised to the mean across replicates at 24 hours and log₂ transformed. Mean values at 96 hours were compared using the one-tailed Student's t-test; ns = not significant.

cohesin and APC/C derives from the additive effect of their simultaneous inhibition, namely weak chromatid cohesion and delayed exit from mitosis [28].

Here we describe yet another mechanism of synthetic lethality involving cohesin that results from the ability of two paralogous genes, *STAG1* and *STAG2*, to compensate for each other. This is due to the gene common evolutionary origin, high sequence conservation and partial retention of original functions. In several cancer types, the somatic inactivation of *STAG2* is selected for due to its tumour suppressor role. However,

this yields mutated cells that become dependent on *STAG1* and sensitive to its inhibition. Our data on SK-ES-1 cells, which have inactive *STAG2* gene, show that this vulnerability can be exploited to specifically target *STAG2*-altered cancers by developing specific *STAG1* inhibitors. Moreover, it has been recently reported that *STAG2* inactivation confers resistance to BRAF inhibitors in melanoma [29]. The vulnerability of *STAG2*-deficient cells towards *STAG1* inhibition may help overcome the onset of this resistance. Paralog dependencies that create cancer vulnerabilities have already been described




Figure 5: Synthetic lethality between *STAG1* and *STAG2* via double gene editing. Legend: (A) Schematic representation of *STAG1* and *STAG2* double gene editing using a lentiviral vector. CAL-51 L161fs-STAG2 and CAL-51 Cas9 cells were infected with the STAG1-Cas9 lentiviral vector and subjected to puromycin selection to produce *STAG1-STAG2* and *STAG1* edited cells, respectively. (B) Crystal violet staining of CAL-51 *STAG1* and *STAG1-STAG2* edited cells ten days after puromycin selection. Less than 150 cells were counted in CAL-51 *STAG1-STAG2* edited cells as compared to around 200,000 CAL-51 *STAG1* edited cells. (C) Schematic representation of the *STAG1* and *STAG2* double gene editing using the vf-CRISPR system. *STAG1* or *EMX1* were edited using the vf-CRISPR system on CAL-51 L161fs-STAG2 and CAL-51 Cas9 cells to generate *STAG1-STAG2* or *EMX1-STAG2* or *STAG1* or *EMX1* edited cells, respectively. (D) Representative T7E1 assay on *EMX1* and *STAG1* edited regions in CAL-51 Cas9 and CAL-51 L161fs-STAG2 cells. (E) Quantification of *EMX1* and *STAG1* gene editing in CAL-51 Cas9 and CAL-51 L161fs-STAG2 cells. Each gene editing was repeated three times and each time the percentage of editing was quantified using ImageJ. Barplots show the mean percentage of gene editing and associated standard errors across replicates. One-tailed Student's t-test was used to assess statistical significance and corresponding p-values are shown; ns = not significant.

for another chromatin-related complex, the SWI/SNF complex. In this case, cancer cells lacking *SMARCA4* or *ARID1A*, two core components of the SWI/SNF complex, become dependent on the corresponding paralogs, *SMARCA2* and *ARID1B*, respectively [30–33]. As a result, the SWI/SNF complex has attracted a great deal of attention for the development of targeted cancer therapies [34, 35]. Our results suggest that paralog dependency is a general mechanism to buffer single gene loss. As such, it is a powerful strategy to discover cancer vulnerabilities [10].

Synthetic dependencies are often difficult to validate experimentally because of their context specificity, partial silencing and widespread off-target effects of common approaches based on RNA interference [9]. To prove that the synthetic lethality between *STAG1* and *STAG2* is context independent, we have tested their genetic interaction in several cancer cell lines where the two genes have variable mutational and copy number status. As already reported in the literature [14, 16, 36], we confirm that the impairment of either STAG paralog alone has a context-specific effect on cell proliferation. In our experiments, blocking *STAG1* or *STAG2* has either no effect or can slightly reduce cell proliferation. However, the concomitant blockade of both genes leads to substantially lower cell growth in all cell lines that we have tested. Moreover, we have induced gene inhibition with both RNA interference and gene editing, obtaining comparable results in all cases. Our vf-CRISPR-based system induces stable gene KO through the formation of a transient Cas9-crRNA-tracrRNA complex. This represents a major advantage to reduce off-target effects that are likely to occur when all CRISPR-Cas9 components are stably expressed [37]. Similar vf-CRISPR approaches have recently been used to induce gene editing *in vitro* [38–40] and *in vivo* [41–43]. In most of these studies, gRNAs are first generated via *in vitro* transcription and then transfected with Cas9 into the cells. Alternatively, all CRISPR-Cas9 components are injected directly into the cells. Here, we further simplify this approach to prove that a simple transfection is able to induce editing of single and multiple genes and can be efficiently applied to prove genetic interactions.

MATERIALS AND METHODS

STAG1 and *STAG2* somatic alterations in TCGA and cancer cell line project

Somatic mutations (single nucleotide variants and small indels), segmented copy numbers and RNA sequencing data were downloaded from TCGA Data Matrix portal (Level 3, <https://tcga-data.nci.nih.gov/docs/publications/tcga/>) for 31 cancer types. Only non-hypermuted samples with a number of mutations within the third quartile of the distribution of mutations for the corresponding cancer type were further retained. *STAG1* and *STAG2* were considered as somatically inactive if they

acquired LoF alterations or damaging alterations. LoF alterations were identified as homozygous gene deletions, truncating mutations (stopgain, stoploss, frameshift indels) or multiple hits (combination of heterozygous gene deletions, truncating and damaging mutations). Damaging alterations were defined as missense and splicing mutations with predicted damaging effects on the protein. Missense mutations were considered damaging if supported by at least five out of eight function-based scores (SIFT [44], PolyPhen-2 HDIV [45], PolyPhen-2 HVAR [45], MutationTaster [46], MutationAssessor [47], LTR [48] and FATHMM [49]) or two out of three conservation-based scores (PhyloP [50], GERP++ RS [51], SiPhy [52]). Splicing mutations were predicted as damaging if supported by at least one ensemble score of dbcsSNV [53]. *STAG1* and *STAG2* were considered deleted if their copy numbers (CN) were <0.5 (homozygous deletion) or <1.5 (heterozygous deletion). CN was measured as

$$CN = 2^{\text{segment mean}} \times 2$$

where segment mean is the segment copy number of *STAG1* or *STAG2* genomic regions.

To compare the expression of mutated and WT *STAG1* and *STAG2*, we converted either the Expectation-Maximization (RSEM) or the Reads Per Kilobase per Million mapped reads (RPKM) into transcripts per million (TPM). Starting from RPKM, TPM were calculated as:

$$TPM(STAG1, STAG2) = \frac{RPKM(STAG1, STAG2)}{\sum_i RPKM(STAG1, STAG2)} \times 10^6$$

RSEM were multiplied by one million to obtain the corresponding TPM.

STAG1 and *STAG2* somatic mutations and Affymetrix U219 expression data in 971 cancer cell lines were obtained from the cancer Cell Lines Project (CLP, http://cancer.sanger.ac.uk/cell_lines). LoF alterations were defined as stopgain, stoploss and frameshift indels. Damaging mutations were identified from the CLP annotation. The expression levels of *STAG1* and *STAG2* were derived from CLP and measured as Z-scores of Robust Multiarray Average (RMA)-normalised expression values [54].

Cell lines

The cell lines used in this study (CAL-51, MCF-7, SK-ES-1, U2OS, MFE-319 and RT-112) were all validated by short tandem repeat analysis. Cells were grown at 37°C and five per cent CO₂ in DMEM 10% FBS (CAL-51, U2OS), DMEM 10% FBS 0.01 mg/ml human recombinant insulin (MCF-7), McCoy's 20% calf serum (SK-ES-1), DMEM-RPMI 20% FBS (MFE-319) and RPMI 10% FBS (RT-112). To confirm the *STAG2* mutation in SK-ES-1 cells, genomic DNA was extracted using GenElute mammalian genomic DNA miniprep

kit (Sigma-Aldrich) according to the manufacturer's protocol. Sanger sequencing was performed after PCR amplification of a 634-base-pair-long genomic region surrounding the *STAG2* mutated position as annotated in CLP (Supplementary Table 2).

siRNA transfection

Transfection was performed with lipofectamine RNAiMAX (Thermo Fisher Scientific) and mission pre-designed siRNA oligos specific for *STAG1* and *STAG2* (Supplementary Table 2) using two universal negative siRNA oligos as controls (Sigma-Aldrich) following the manufacturer's protocol. For proliferation assays, transfections were performed in 96-well plates, while for RNA and protein extraction, transfections were performed in 24-well plates and 6-well plates, respectively. In all assays, the total concentration of the RNAi oligos was 50 nM (25 nM for each siRNA). For the double KD, the two *STAG1* and *STAG2* siRNA oligos were mixed. For the single KD, the siRNA specific either for *STAG1* or *STAG2* was combined with one of the universal negative siRNA oligos. For the control, the two universal negative siRNA oligos were used.

Quantitative RT-PCR

Total RNA was extracted using GenElute mammalian total RNA miniprep kit (Sigma-Aldrich). Reverse transcription was performed starting from 175 ng RNA using GoScript™ reverse transcription system (Promega). cDNAs were subjected to quantitative PCR using pre-designed SYBR green primers (Sigma-Aldrich; Supplementary Table 2) and SYBR Green JumpStart Taq ReadyMix™ (Sigma-Aldrich). Gene expression levels were assessed in triplicate using ViiA7 thermal cycler (Applied Biosystems) and the average expression level across triplicates (e) was relativized to the average expression level of β -2-microglobulin (c):

$$r = e - c$$

where r is the relative gene expression.

The fold change (fc) between the relative gene expression after KD (r_{KD}) and the relative gene expression in the control condition (r_c) was calculated as:

$$fc = 2^{(r_c - r_{KD})}$$

Each experiment was repeated in biological duplicate.

Western blot analysis

CAL-51 cells were seeded at 70% confluence in 60 mm plates, grown for 48 hours after gene KD or for 24 hours after CRISPR editing, washed twice with PBS and lysed with RIPA buffer. Protein amounts present in the cell

lysates were measured using Pierce BCA protein assay kit (Thermo Fisher Scientific). Five to ten micrograms of protein were loaded in TruPAGE™ precast gels (Sigma-Aldrich). *STAG1*, *STAG2* or *GAPDH* proteins were detected by incubating membranes overnight with anti-*STAG1* prestige rabbit antibody at 1/150 dilution (Sigma Life Science, HPA035015), anti-*STAG2* mouse antibody 1/500 dilution (Sigma-Aldrich, WHO0010735M1) or anti-*GAPDH* mouse antibody 1/10000 dilution (MAB374, clone 6C5, EMD Millipore), respectively. After washing with 0.01% PBS-Tween 20, membranes were incubated with peroxidase-conjugated anti-mouse or anti-rabbit antibodies (1:5000, Mouse IgG HRP-linked Whole Ab NA934 and Rabbit IgG HRP-linked Whole Ab NA934, GE Healthcare) for 45 minutes and washed before detection by chemiluminescence (ECL, GE Healthcare).

Proliferation assays and crystal violet staining

Cell proliferation was measured every 24 hours for four days, starting one day after transfection using either CellTiter-Fluor™ cell viability assay (Promega) or crystal violet staining followed by dye extraction using methanol and optical density measured at 570 nm [55]. Briefly, 5×10^3 cells/well transfected with *STAG1*, *STAG2* or negative siRNAs were seeded on 96-well plates in a final volume of 100 μ l per well. For the CellTiter-Fluor™ cell viability assay (Promega), at each time point, 20 μ l of the diluted reagent (10 μ l of the GF-AFC Substrate in 2 ml of Assay Buffer) was added to each well. After one hour and 30 minutes, fluorescence was measured at 380–400 nm_{Ex}/505 nm_{Em} using a Fusion alpha-FP (Perkin Elmer). Each condition was assessed in triplicate and the whole experiment was repeated at least twice. Crystal violet staining was used to visualise the effect of *STAG1* and *STAG2* KD on CAL-51 cells. Briefly, 70000 cells were seeded on 12-well plates and transfected with the universal negative control, *STAG1*, *STAG2* or *STAG1* and *STAG2* siRNAs. After five days, cells were fixed with ice-cold 100% methanol and stained with 0.1% crystal violet. After 30 minutes, cells were washed three times with water and dried.

STAG1 editing with CRISPR vectors and T7E1 assay

CAL-51 cells were transduced with the lentiviral vector (pLV-U6g-EPCG) containing Cas9sp, the puromycin resistance marker and a *STAG1* gRNA (Sigma-Aldrich). The gRNA was composed of a universal 86-nucleotide-long tracrRNA and 20-nucleotide-long *STAG1*-specific crRNA (Supplementary Table 2). Forty-eight hours after infection, stably transduced cells were selected with puromycin (6 μ g/ml). U2OS, MFE-319 and RT-112 cells were transfected with a vector containing Cas9sp, the Orange Fluorescent Protein (OFP) reporter (GeneArt Nuclease, Thermo Fisher Scientific) and the

STAG1 gRNA1a (Supplementary Table 2). Forward and reverse strand oligos corresponding to STAG1 gRNA1a were synthesized with 3' overhangs nucleotides according to the manufacturer's protocol. Resulting oligos were annealed and cloned into the linearized GeneArt Nuclease vector. After verification of STAG1 gRNA integration via Sanger sequencing, cells were transfected using Fugene6 (Promega) and OFP positive cells were sorted after 72 hours. The per cent of edited cells was assessed two weeks after selection or one week after OFP positive cell sorting using the T7 endonuclease 1 (T7E1) assay (New England Biolabs), following the manufacturer's protocol. Briefly, the genomic site targeted by the STAG1 crRNAs was amplified from 100 ng of genomic DNA extracted with GenElute genomic DNA extraction kit (Sigma-Aldrich), using Q5 Hot Start High-Fidelity 2X Master Mix (New England Biolabs) and specific primers (Supplementary Table 2). Amplicons of 700-800 base pairs were purified using GenElute PCR clean-up kit (Sigma-Aldrich) and 200 ng of PCR products were denatured, annealed and digested with the T7 endonuclease 1 enzyme (New England Biolabs) for 15 minutes. Digested products were run on a two per cent agarose gel and the intensity of bands corresponding to the full-length amplicon and, in presence of editing, the two digested fragments were quantified with ImageJ [56] and GelAnalyzer (<http://www.gelanalyzer.com/index.html>). Each band was quantified three times and the whole experiment was repeated three times.

Generation of CAL-51-Cas9 expressing cells and gene editing with vector-free CRISPR

CAL-51 cells were transduced with a lentiviral vector containing *Cas9sp* (GeCKO-tEflaCas9Blast, Sigma-Aldrich) and blasticidin resistance marker. After 10 days of treatment with blasticidin (25 ug/ml), resistant cells were selected and *Cas9sp* expression was verified via PCR (Supplementary Table 2). STAG1 and STAG2 crRNAs (Sigma-Aldrich, Supplementary Table 2) were co-transfected with 69-mer tracrRNA (Sigma-Aldrich) together with GeneArt Platinum Cas9 nuclease (Life Technologies) using lipofectamine CRISPRMAX (Life Technologies). The per cent of edited cells was assessed 72 hours after transfection using the T7E1 assay (New England Biolabs) as reported above.

Isolation and identification of STAG2 edited clones

STAG2 was edited on 200,000 CAL-51 Cas9 expressing cells (CAL-51-Cas9) using the vector-free (vf) CRISPR method and the STAG2 2b crRNA (Supplementary Table 2). Seventy-two hours after editing, cells were dissociated with trypsin, counted and seeded as single cells on 96-well plates. Seven clones were further assessed to evaluate the editing status using High Resolution Melting

Assay (HRMA). Genomic DNA was extracted from each clone and from CAL-51-Cas9 cells and a 125-base-pair-long segment surrounding the STAG2b edited region was amplified with specific primers (Supplementary Table 2) using MeltDoctor HRM master mix (Applied Biosystems) following the manufacturer's cycling conditions. The Applied Biosystems High Resolution Melting Software was used to review the melt curves and distinguish between homozygous and heterozygous edited clones as compared to WT. The homozygous deletion of an eight-base-pair-long segment was confirmed with Sanger sequencing (Supplementary Table 2).

Author contributions

F.D.C. conceived and directed the study; L.B. performed all experiments with the support of L.M.; M.C. and N.D. analysed the data; F.D.C. and L.B. wrote the manuscript. All authors reviewed and approved the manuscript.

ACKNOWLEDGMENTS

We thank the Cell Services Scientific Technology Platform of the Francis Crick Institute (London) for assistance with cell culture and Professor Andy Tutt (Breast Cancer Now Research Unit, King's College London) for CAL-51 and MCF-7 cells.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

FUNDING

We acknowledge the support of the Guy's and St Thomas' Charity and King's College London. Open access for this article was funded by King's College London.

REFERENCES

1. Haering CH, Farcas AM, Arumugam P, Metson J, Nasmyth K. The cohesin ring concatenates sister DNA molecules. *Nature*. 2008; 454:297-301.
2. Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. *Annu Rev Genet*. 2009; 43:525-558.
3. Losada A. Cohesin in cancer: chromosome segregation and beyond. *Nat Rev Cancer*. 2014; 14:389-393.
4. Mehta GD, Kumar R, Srivastava S, Ghosh SK. Cohesin: functions beyond sister chromatid cohesion. *FEBS Lett*. 2013; 587:2299-2312.
5. An O, Dall'Olio GM, Mourikis TP, Ciccarelli FD. NCG 5.0: updates of a manually curated repository of cancer genes and associated properties from cancer mutational screenings. *Nucleic Acids Res*. 2016; 44:D992-999.

6. Solomon DA, Kim T, Diaz-Martinez LA, Fair J, Elkahoun AG, Harris BT, Toretsky JA, Rosenberg SA, Shukla N, Ladanyi M, Samuels Y, James CD, Yu H, et al. Mutational inactivation of STAG2 causes aneuploidy in human cancer. *Science*. 2011; 333:1039-1043.
7. Welch JS, Ley TJ, Link DC, Miller CA, Larson DE, Koboldt DC, Wartman LD, Lamprecht TL, Liu F, Xia J, Kandoth C, Fulton RS, McLellan MD, et al. The origin and evolution of mutations in acute myeloid leukemia. *Cell*. 2012; 150:264-278.
8. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, Ishikawa S, Sato-Otsubo A, Nagae G, et al. Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. *Nat Genet*. 2013; 45:1232-1237.
9. McLornan DP, List A, Mufti GJ. Applying synthetic lethality for the selective targeting of cancer. *N Engl J Med*. 2014; 371:1725-1735.
10. Cereda M, Mourikis TP, Ciccarelli FD. Genetic Redundancy, Functional Compensation, and Cancer Vulnerability. *Trends in Cancer*. 2016; 2:160-162.
11. Canudas S, Smith S. Differential regulation of telomere and centromere cohesion by the Scc3 homologues SA1 and SA2, respectively, in human cells. *J Cell Biol*. 2009; 187:165-173.
12. Remeseiro S, Cuadrado A, Carretero M, Martinez P, Drosopoulos WC, Canamero M, Schildkraut CL, Blasco MA, Losada A. Cohesin-SA1 deficiency drives aneuploidy and tumorigenesis in mice due to impaired replication of telomeres. *EMBO J*. 2012; 31:2076-2089.
13. Kong X, Ball AR Jr, Pham HX, Zeng W, Chen HY, Schmiesing JA, Kim JS, Berns M, Yokomori K. Distinct functions of human cohesin-SA1 and cohesin-SA2 in double-strand break repair. *Mol Cell Biol*. 2014; 34:685-698.
14. Balbas-Martinez C, Sagrera A, Carrillo-de-Santa-Pau E, Earl J, Marquez M, Vazquez M, Lapi E, Castro-Giner F, Beltran S, Bayes M, Carrato A, Cigudosa JC, Dominguez O, et al. Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. *Nat Genet*. 2013; 45:1464-1469.
15. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014; 507:315-322.
16. Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahoun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, et al. Frequent truncating mutations of STAG2 in bladder cancer. *Nat Genet*. 2013; 45:1428-1430.
17. Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. *Nat Genet*. 2013; 45:1459-1463.
18. Crompton BD, Stewart C, Taylor-Weiner A, Alexe G, Kurek KC, Calicchio ML, Kiezun A, Carter SL, Shukla SA, Mehta SS, Thorner AR, de Torres C, Lavarino C, et al. The genomic landscape of pediatric Ewing sarcoma. *Cancer Discov*. 2014; 4:1326-1341.
19. Tirode F, Surdez D, Ma X, Parker M, Le Deley MC, Bahrami A, Zhang Z, Lapouble E, Grossetete-Lalami S, Rusch M, Reynaud S, Rio-Frio T, Hedlund E, et al. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations. *Cancer Discov*. 2014; 4:1342-1353.
20. Brennan CW, Verhaak RG, McKenna A, Campos B, Nourbakhsh H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhi R, Bernard B, Wu CJ, et al. The somatic genomic landscape of glioblastoma. *Cell*. 2013; 155:462-477.
21. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, Greninger P, Thompson IR, Luo X, Soares J, Liu Q, Iorio F, Surdez D, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. *Nature*. 2012; 483:570-575.
22. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. *Science*. 2013; 339:819-823.
23. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. *Nat Protoc*. 2013; 8:2281-2308.
24. Stewart E, Goshorn R, Bradley C, Griffiths LM, Benavente C, Twarog NR, Miller GM, Caufield W, Freeman BB 3rd, Bahrami A, Pappo A, Wu J, Loh A, et al. Targeting the DNA repair pathway in Ewing sarcoma. *Cell Rep*. 2014; 9:829-841.
25. Bailey ML, O'Neil NJ, van Pel DM, Solomon DA, Waldman T, Hieter P. Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. *Mol Cancer Ther*. 2014; 13:724-732.
26. O'Neil NJ, van Pel DM, Hieter P. Synthetic lethality and cancer: cohesin and PARP at the replication fork. *Trends Genet*. 2013; 29:290-297.
27. McLellan JL, O'Neil NJ, Barrett I, Ferree E, van Pel DM, Ushey K, Sipahimalani P, Bryan J, Rose AM, Hieter P. Synthetic lethality of cohesins with PARPs and replication fork mediators. *PLoS Genet*. 2012; 8:e1002574.
28. de Lange J, Faramarz A, Oostra AB, de Menezes RX, van der Meulen IH, Rooimans MA, Rockx DA, Brakenhoff RH, van Beusechem VW, King RW, de Winter JP, Wolthuis RM. Defective sister chromatid cohesion is synthetically lethal with impaired APC/C function. *Nat Commun*. 2015; 6:8399.

29. Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, Cai L, Gu L, Li M, Lee JH, Mitra D, Fisher DE, Sullivan RJ, et al. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. *Nat Med.* 2016; 22:1056-1061.
30. Oike T, Ogiwara H, Tominaga Y, Ito K, Ando O, Tsuta K, Mizukami T, Shimada Y, Isomura H, Komachi M, Furuta K, Watanabe SI, Nakano T, et al. A Synthetic Lethality–Based Strategy to Treat Cancers Harboring a Genetic Deficiency in the Chromatin Remodeling Factor BRG1. *Cancer Research.* 2013; 73:5508-5518.
31. D'Antonio M, Guerra RF, Cereda M, Marchesi S, Montani F, Nicassio F, Di Fiore PP, Ciccarelli FD. Recessive cancer genes engage in negative genetic interactions with their functional paralogs. *Cell Rep.* 2013; 5:1519-1526.
32. Hoffman GR, Rahal R, Buxton F, Xiang K, McAllister G, Frias E, Bagdasarian L, Huber J, Lindeman A, Chen D, Romero R, Ramadan N, Phadke T, et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. *Proceedings of the National Academy of Sciences.* 2014; 111:3128-3133.
33. Helming KC, Wang X, Wilson BG, Vazquez F, Haswell JR, Manchester HE, Kim Y, Kryukov GV, Ghandi M, Aguirre AJ, Jagani Z, Wang Z, Garraway LA, et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. *Nat Med.* 2014; 20:251-254.
34. Vangamudi B, Paul TA, Shah PK, Kost-Alimova M, Nottebaum L, Shi X, Zhan Y, Leo E, Mahadeshwar HS, Protopopov A, Futreal A, Tieu TN, Peoples M, et al. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies. *Cancer Res.* 2015; 75:3865-3878.
35. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, Schultz DC, Liu Q, Shih IeM, Conejo-Garcia JR, Speicher DW, Zhang R. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. *Nat Med.* 2015; 21:231-238.
36. Kim JS, He X, Orr B, Wutz G, Hill V, Peters JM, Compton DA, Waldman T. Intact Cohesion, Anaphase, and Chromosome Segregation in Human Cells Harboring Tumor-Derived Mutations in STAG2. *PLoS Genet.* 2016; 12:e1005865.
37. Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. *Genome Res.* 2014; 24:1012-1019.
38. Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N, Ranganathan S, Ravinder N, Chesnut JD. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. *J Biotechnol.* 2015; 208:44-53.
39. Yu X, Liang X, Xie H, Kumar S, Ravinder N, Potter J, de Mollerat du Jeu X, Chesnut JD. Improved delivery of Cas9 protein/gRNA complexes using lipofectamine CRISPRMAX. *Biotechnol Lett.* 2016; 919-929.
40. Anderson EM, Haupt A, Schiel JA, Chou E, Machado HB, Strezoska Z, Lenger S, McClelland S, Birmingham A, Vermeulen A, Smith A. Systematic analysis of CRISPR-Cas9 mismatch tolerance reveals low levels of off-target activity. *J Biotechnol.* 2015; 211:56-65.
41. Paix A, Folkmann A, Rasoloson D, Seydoux G. High Efficiency, Homology-Directed Genome Editing in *Caenorhabditis elegans* Using CRISPR-Cas9 Ribonucleoprotein Complexes. *Genetics.* 2015; 201:47-54.
42. Kotani H, Taimatsu K, Ohga R, Ota S, Kawahara A. Efficient Multiple Genome Modifications Induced by the crRNAs, tracrRNA and Cas9 Protein Complex in Zebrafish. *PLoS One.* 2015; 10:e0128319.
43. Aida T, Chiyo K, Usami T, Ishikubo H, Imahashi R, Wada Y, Tanaka KF, Sakuma T, Yamamoto T, Tanaka K. Cloning-free CRISPR/Cas system facilitates functional cassette knock-in in mice. *Genome Biol.* 2015; 16:87.
44. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nat Protoc.* 2009; 4:1073-1081.
45. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR. A method and server for predicting damaging missense mutations. *Nat Methods.* 2010; 7:248-249.
46. Schwarz JM, Rodelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods.* 2010; 7:575-576.
47. Reva B, Antipin Y, Sander C. Predicting the functional impact of protein mutations: application to cancer genomics. *Nucleic Acids Res.* 2011; 39:e118.
48. Chun S, Fay JC. Identification of deleterious mutations within three human genomes. *Genome Res.* 2009; 19:1553-1561.
49. Shihab HA, Gough J, Cooper DN, Day IN, Gaunt TR. Predicting the functional consequences of cancer-associated amino acid substitutions. *Bioinformatics.* 2013; 29:1504-1510.
50. Pollard KS, Hubisz MJ, Rosenbloom KR, Siepel A. Detection of nonneutral substitution rates on mammalian phylogenies. *Genome Res.* 2010; 20:110-121.
51. Davydov EV, Goode DL, Sirota M, Cooper GM, Sidow A, Batzoglou S. Identifying a high fraction of the human genome to be under selective constraint using GERP++. *PLoS Comput Biol.* 2010; 6:e1001025.
52. Garber M, Guttman M, Clamp M, Zody MC, Friedman N, Xie X. Identifying novel constrained elements by exploiting biased substitution patterns. *Bioinformatics.* 2009; 25:i54-62.

53. Jian X, Boerwinkle E, Liu X. In silico prediction of splice-altering single nucleotide variants in the human genome. *Nucleic Acids Res.* 2014; 42:13534-13544.
54. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. *Nature.* 2012; 483:603-607.
55. Feoktistova M, Geserick P, Leverkus M. Crystal Violet Assay for Determining Viability of Cultured Cells. *Cold Spring Harb Protoc.* 2016; 2016:pdb prot087379.
56. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. *Nat Methods.* 2012; 9:671-675.
57. Letunic I, Doerks T, Bork P. SMART: recent updates, new developments and status in 2015. *Nucleic Acids Res.* 2015; 43:D257-260.
58. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, Ritchey JK, Young MA, Lamprecht T, McLellan MD, McMichael JF, Wallis JW, Lu C, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. *Nature.* 2012; 481:506-510.
59. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. *N Engl J Med.* 2013; 368:2059-2074.
60. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, Mauch J, Kelkenberg-Schade S, Haldemann B, Fries T, Kronke J, Kuhn MW, Paschka P, Kayser S, Wolf S, Gaidzik VI, et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. *Blood.* 2012; 120:e83-92.
61. Papaemmanuil E, Rapado I, Li Y, Potter NE, Wedge DC, Tubio J, Alexandrov LB, Van Loo P, Cooke SL, Marshall J, Martincorena I, Hinton J, Gundem G, et al. RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. *Nat Genet.* 2014; 46:116-125.
62. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, Larson DE, McLellan MD, Dooling D, Abbott R, Fulton R, Magrini V, Schmidt H, et al. Clonal Architecture of Secondary Acute Myeloid Leukemia. *New England Journal of Medicine.* 2012; 366:1090-1098.
63. Brohl AS, Solomon DA, Chang W, Wang J, Song Y, Sindiri S, Patidar R, Hurd L, Chen L, Shern JF, Liao H, Wen X, Gerard J, et al. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation. *PLoS Genet.* 2014; 10:e1004475.